Company profile for Reviva Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a fast growing privately held, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nervous system (CNS), cardiovascula...
Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a fast growing privately held, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic and inflammatory diseases. The leadership and management team is comprised of highly successful and experienced professionals from the pharmaceutical industry.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
19925 Stevens Creek Blvd., Suite 100 Cupertino, CA 95014
Telephone
Telephone
+1 408 816 1470
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/13/3187825/0/en/Reviva-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186179/0/en/Reviva-to-Present-Anti-Inflammatory-Impacts-of-Brilaroxazine-in-Schizophrenia-from-the-RECOVER-12-month-Open-Label-Extension-Trial-at-Neuroscience-2025.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184521/0/en/Reviva-Announces-Grant-of-European-Patent-Covering-Use-of-Brilaroxazine-for-the-Treatment-of-Pulmonary-Fibrosis.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/10/29/3176363/0/en/Reviva-to-Participate-in-the-Spartan-Capital-Securities-Second-Annual-Investor-Conference.html

GLOBENEWSWIRE
29 Oct 2025

https://www.globenewswire.com/news-release/2025/10/28/3175313/0/en/Reviva-to-Present-Negative-Symptom-Data-for-Brilaroxazine-in-Schizophrenia-from-the-Phase-3-RECOVER-Double-Blind-and-Open-Label-Extension-Trials-at-the-CNS-Summit-2025.html

GLOBENEWSWIRE
28 Oct 2025

https://www.globenewswire.com/news-release/2025/10/07/3162948/0/en/Reviva-to-Participate-in-Key-Opinion-Leader-Webinar-Hosted-by-Alliance-Global-Partners.html

GLOBENEWSWIRE
07 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty